#USA #Burlington, MA #Consano Bio #C-1101 #Chronic Sciatica

Overview

Consano Bio, Inc., a clinical-stage biotechnology company, is set to present its groundbreaking therapy C-1101 at two prominent industry conferences this October. These events will provide a platform to discuss the potential of C-1101 in transforming the treatment landscape for chronic sciatica.

Conference Details

• - Align Summit: This annual partnering conference hosted by MassBio will take place on October 15, 2026 in Boston, MA. Consano will be featured on the presentation schedule, discussing the advancements in biologics and therapeutics for orthopedic conditions.
• - BioFuture Conference: Scheduled for October 28-29, 2026, in New York, NY, this event will include Consano’s contributions through a panel discussion titled “BioFuture Now: Pioneering the Future of Biopharma Breakthroughs.” This discussion is set for October 28, from 10:00 AM to 10:55 AM, ET.

About C-1101

C-1101 is at the forefront of Consano Bio's innovative approach, representing the first pharmaceutical therapy of its kind designed specifically to target lumbosacral radiculopathy (LSR), commonly known as chronic sciatica. The condition stems from damage to nerve roots in the lumbar spine, which can lead to debilitating pain, numbness, and weakness radiating into the legs. Currently, there are no FDA-approved pharmaceuticals available for this condition, despite its prevalence and substantial impact on patients’ quality of life.

C-1101 is a novel, platelet-derived multi-protein biologic therapeutic that operates by modulating inflammation and accelerating cellular repair at injury sites. Key constituents like cytokines and growth factors are delicately balanced in this formulation to stimulate the body’s natural healing processes. Administered via epidural injection, it aims to deliver essential proteins directly to the site of nerve injury, thereby enhancing treatment efficacy.

Importance of the Conferences

At both conferences, key executives from Consano Bio will engage with registered investors and prospective collaborators. They will highlight the company’s strategic direction, clinical development milestones, and recent achievements in biopharmaceutical innovation. This is a crucial opportunity to connect with stakeholders who can support the advancement of C-1101 through funding and partnerships.

Conclusion

Consano Bio's presentation at these upcoming conferences signifies an exciting development in the realm of innovative therapeutics for chronic conditions such as sciatica. As the company prepares to unveil the capabilities and applications of C-1101, the anticipation surrounding its potential to change lives is palpable. The firm is dedicated to reimagining the landscape of treatment for chronic orthopedic pain, making strides toward improving patient outcomes and quality of life.

For more about Consano Bio and its breakthrough innovations, visit Consano Bio's website.